Wayne S. Mulcahy
Corporate Officer/Principal chez Alita Pharmaceuticals, Inc.
Provenance du réseau au premier degré de Wayne S. Mulcahy
Entité | Type d'entité | Industrie | |
---|---|---|---|
Alita Pharmaceuticals, Inc.
Alita Pharmaceuticals, Inc. Pharmaceuticals: MajorHealth Technology Alita Pharmaceuticals, Inc. develops, manufactures and distributes urologic and female healthcare products. It offers product testing, research and development services. The company was founded by Carole S. Ben-Maimon and Warburg Pincus in September 2006 and is headquartered in Radnor, PA.
3
| Private Company | Pharmaceuticals: Major | 3 |
Graphique Sociétés connectées au second degré
Relation dans plusieurs entreprises
Sociétés connectées à Wayne S. Mulcahy via son réseau personnel
Société | Secteur | Personnes liées | Poste principal |
---|---|---|---|
Warburg Pincus LLC
Warburg Pincus LLC Investment ManagersFinance Warburg Pincus LLC (Warburg Pincus) is a private equity subsidiary of Warburg Pincus & Company US LLC founded in 1966. The firm is headquartered in New York. | Investment Managers | Private Equity Investor | |
Apollon, Inc.
Apollon, Inc. BiotechnologyHealth Technology Part of Pfizer Inc., Apollon, Inc. is a company that develops non viral DNA-based vaccines. The company is based in Malvern, PA. Apollon was acquired by Wyeth LLC, part of Pfizer Inc. from October 15, 2009 on May 11, 1998. The company was founded by Vincent R. Zurawski. | Biotechnology | Corporate Officer/Principal | |
Sanofi-Aventis U.S. LLC
Sanofi-Aventis U.S. LLC Pharmaceuticals: MajorHealth Technology Sanofi-Aventis U.S. LLC engages in the provision of pharmaceutical products. It discovers, develops, produces and markets innovative therapies. The firm extensive research and development efforts are focused on health care challenges in cardiology, oncology and internal medicine, as well as metabolic diseases, central nervous system disorders, ophthalmology and vaccines. The company is headquartered in Bridgewater, NJ. | Pharmaceuticals: Major | Corporate Officer/Principal | |
Shire ViroPharma, Inc.
Shire ViroPharma, Inc. Pharmaceuticals: MajorHealth Technology Shire ViroPharma, Inc. develops and manufactures drugs. It offers treatment for prophylaxis of hereditary angioedema, as well as capsules for the treatment of antibiotic associated pseudomembranous colitis caused by Clostridium difficile infection (CDI) and enterocolitis. The company was founded by Claude H. Nash and Mark A. McKinlay in September 1994 and is headquartered in Exton, PA. | Pharmaceuticals: Major | Corporate Officer/Principal | |
Purdue University | College/University | Undergraduate Degree | |
University of Wisconsin | College/University | Doctorate Degree | |
JOHNSON MATTHEY PLC | Chemicals: Major Diversified | Corporate Officer/Principal | |
HONEYWELL INTERNATIONAL INC. | Aerospace & Defense | Corporate Officer/Principal | |
STADA ARZNEIMITTEL | Pharmaceuticals: Major | President | |
Drexel University | College/University | Graduate Degree | |
University of Pennsylvania | College/University | Undergraduate Degree | |
Radionetics Oncology, Inc.
Radionetics Oncology, Inc. Pharmaceuticals: MajorHealth Technology Radionetics Oncology, Inc. is a clinical stage radiopharmaceutical company based in Menlo Park, CA. Radionetics Oncology, Inc. focuses on the discovery and development of novel radiotherapeutics for the treatment of various oncology indications. Radionetics Oncology spun out of Crinetics Pharmaceuticals and is supported by Frazier Life Sciences, 5AM Ventures, DCVC Bio, Crinetics Pharmaceuticals, and GordonMD Investments. The company is advancing a pipeline of small molecule radioligands that target G-protein coupled receptors to treat a wide range of cancers, including adrenocortical carcinoma, breast cancer, and lung cancer. The company's platform technology uses nonpeptide, small molecule targeting to deliver therapeutic radioisotopes selectively to tumors expressing peptide receptors. The company's pipeline consists of multiple lead drug candidates, and they are conducting additional drug discovery efforts in collaboration with Crinetics Pharmaceuticals. The market for radiopharmaceuticals is expected to rise to $12.6 billion by 2027. The company was founded by Scott R. Struthers, and Paul A. Grayson has been the CEO since 2024. | Pharmaceuticals: Major | Chief Executive Officer | |
Sprout Group
Sprout Group Investment ManagersFinance Sprout Group (Sprout) is venture capital subsidiary of Credit Suisse Private Equity LLC founded in 1969. The firm headquartered in New York. | Investment Managers | Corporate Officer/Principal | |
AFYX Therapeutics AS
AFYX Therapeutics AS Miscellaneous Commercial ServicesCommercial Services AFYX Therapeutics AS engages in research and development of pharmaceutical drugs. It develops a platform designed to deliver a pharmaceutical drug uni-directional to a mucosal surface. The company was founded in May 2014 and is headquartered in Virum, Denmark. | Miscellaneous Commercial Services | Chief Executive Officer | |
CONNECT
CONNECT Miscellaneous Commercial ServicesCommercial Services CONNECT creates and scales companies in the technology and life sciences sectors. It creates an environment in which entrepreneurs and C-suite executives have access to the people, capital, and technology resources. The organization was founded in 1985 and is headquartered in San Diego, CA. | Miscellaneous Commercial Services | Director/Board Member | |
POSEIDA THERAPEUTICS, INC. | Biotechnology | President | |
Transposagen Biopharmaceuticals, Inc.
Transposagen Biopharmaceuticals, Inc. BiotechnologyHealth Technology Transposagen Biopharmaceuticals, Inc. operates as a biotechnology company. Its products and services include piggyBac Reagents, cell engineering services and gene editing reagents & kits. The company was founded by Ostertag M. Eric in 2005 and is headquartered in Lexington, KY. | Biotechnology | Director/Board Member | |
Harvard College | College/University | Undergraduate Degree | |
The Wharton School of the University of Pennsylvania | College/University | Masters Business Admin | |
Perelman School of Medicine | College/University | Doctorate Degree | |
LIGAND PHARMACEUTICALS INCORPORATED | Pharmaceuticals: Major | Director of Finance/CFO | |
Allos Therapeutics, Inc.
Allos Therapeutics, Inc. Pharmaceuticals: MajorHealth Technology Allos Therapeutics, Inc. is a biopharmaceutical company committed to the development and commercialization of innovative anti-cancer therapeutics. It focuses on the development and commercialization FOLOTYN a pralatrexate injection. FOLOTYN is a folate analogue metabolic inhibitor designed to accumulate preferentially in cancer cells. It targets the inhibition of dihydrofolate reductase, or DHFR, an enzyme critical in the folate pathway, thereby interfering with DNA and RNA synthesis and triggering cancer cell death. Allos Therapeutics is also developing FOLOTYN in other hematologic malignancies and solid tumors. The company was founded on September 1, 1992 and is headquartered in Westminster, CO. | Pharmaceuticals: Major | Director/Board Member | |
Talon Therapeutics, Inc.
Talon Therapeutics, Inc. Pharmaceuticals: MajorHealth Technology Talon Therapeutics, Inc. is a biopharmaceutical company, which is engaged in the developing and commercializing new and differentiated cancer therapies. The firm is developing the Marqibo for the treatment of acute lymphoblastic leukemia and other blood cancers including lymphoma. Its Menadione topical lotion is a compound which is developed for the prevention and treatment of skin toxicity associated with epidermal growth factor receptor inhibitors. The company was founded by Mark J. Ahn in 2002 and is headquartered in San Mateo, CA. | Pharmaceuticals: Major | Director/Board Member | |
McKinsey & Co., Inc.
McKinsey & Co., Inc. Miscellaneous Commercial ServicesCommercial Services McKinsey & Co., Inc. provides management consulting services. It specializes in design, marketing and sales, analytics, operations, transformation and restructuring, risk, strategy and corporate finance, and sustainability and resource productivity. The company was founded by James O. McKinsey in 1926 and is headquartered in New York, NY. | Miscellaneous Commercial Services | Corporate Officer/Principal | |
DuPont Merck Pharmaceutical Co.
DuPont Merck Pharmaceutical Co. Pharmaceuticals: MajorHealth Technology Part of Corteva, Inc., DuPont Merck Pharmaceutical Co. is a company that makes pharmaceuticals and drugs. The company is based in Wilmington, DE. DuPont Merck Pharmaceutical was acquired by EIDP, Inc., a subsidiary of Corteva, Inc. from Merck & Co., Inc. on July 01, 1998 for $2,600 million. | Pharmaceuticals: Major | Corporate Officer/Principal |
Statistiques
Internationale
Etats-Unis | 27 |
Royaume-Uni | 2 |
Allemagne | 2 |
Danemark | 2 |
Sectorielle
Health Technology | 14 |
Consumer Services | 8 |
Commercial Services | 4 |
Finance | 3 |
Process Industries | 3 |
Opérationnelle
Corporate Officer/Principal | 12 |
Director/Board Member | 11 |
Undergraduate Degree | 3 |
Independent Dir/Board Member | 3 |
Chief Executive Officer | 2 |
Relations les plus connectées
Insiders | |
---|---|
Nishan de Silva | 18 |
Paul Evans | 8 |
Debra P. Gayda | 7 |
- Bourse
- Insiders
- Wayne S. Mulcahy
- Connexions Sociétés